Hormone-refractory prostate cancer – Diagnostics – Overview of Information and Clinical Research

Diagnosing hormone-refractory prostate cancer involves carefully tracking how the disease responds to treatment and identifying when it stops reacting to standard hormone therapy. Understanding which tests and procedures are used helps patients and their doctors make informed decisions about the next steps in managing this challenging condition.

Introduction: Who Should Undergo Diagnostics

If you have been receiving hormone therapy for prostate cancer, your doctor will want to monitor how your body and the cancer are responding over time. Hormone-refractory prostate cancer, also known as castration-resistant prostate cancer, is diagnosed when the cancer continues to grow despite treatments that have lowered testosterone to very low levels. This name describes a situation where the cancer has learned to grow even when the male hormone testosterone—which normally fuels prostate cancer cells—is reduced to near zero.^[1]

Diagnostics for this condition become especially important when certain signs appear. You should seek diagnostic testing if your prostate-specific antigen, or PSA, level begins to rise while you are on hormone therapy. PSA is a protein made by prostate cells, and its level in the blood can indicate how active the cancer is. If your PSA rises on at least two separate occasions, at least one week apart, this may signal that your cancer is no longer responding to hormone treatment.^[3]

Not everyone experiences symptoms right away when cancer becomes hormone-refractory. Some patients notice no physical changes at all, while others may develop new pain, especially in the bones, or experience urinary problems, fatigue, or other signs that the disease is advancing. Whether or not you have symptoms, regular testing helps catch changes early.^[6]

It is also essential to confirm that your body has reached what doctors call castrate levels of testosterone. This means your testosterone should be very low—typically less than 50 nanograms per deciliter. Surprisingly, even after surgery or medication to reduce testosterone, some men do not reach these low levels. In one study, about 11% of men who had surgery to remove the testicles did not achieve castrate testosterone levels. Without confirming these levels, it is difficult to know whether the cancer is truly hormone-refractory or whether the initial treatment simply did not work as expected.^[1]

⚠️ Important

Before your doctor labels your cancer as hormone-refractory, it is important to check that your testosterone levels are truly at castrate levels. If they are not, adjusting your treatment may help rather than moving to more aggressive therapies.

Diagnostics are also needed if imaging tests such as bone scans, CT scans, or MRI scans show that the cancer is growing or spreading to new areas, even while you continue hormone therapy. These tests provide a picture of where the cancer is in your body and whether it has moved beyond the prostate to bones, lymph nodes, or other organs.^[4]

Diagnostic Methods: Classic Tests Used to Identify the Disease

The process of diagnosing hormone-refractory prostate cancer relies on several types of tests. Each provides a different piece of information that helps doctors understand what is happening inside your body.

PSA Blood Test

The PSA blood test is the most widely used tool for monitoring prostate cancer during and after hormone therapy. When PSA levels begin to rise despite treatment, this is often the first sign that the cancer is becoming hormone-refractory. Doctors look for a pattern of increasing PSA values over time. Specifically, they want to see at least two consecutive rises in PSA, measured at least one week apart, with each test using the same laboratory method to ensure accuracy.^[1]

The PSA level itself is not the only concern. Doctors also calculate the PSA doubling time, which is how long it takes for the PSA level to double. A shorter doubling time often suggests more aggressive cancer that may need treatment sooner, while a longer doubling time may mean the disease is progressing more slowly.^[4]

Although PSA is helpful, it is not perfect. Some prostate cancers stop producing PSA as they become more aggressive, which means the test may not always reflect what the cancer is doing. In such cases, doctors rely more heavily on imaging and other tests.^[8]

Testosterone Level Testing

Measuring testosterone levels in the blood is a critical step in confirming hormone-refractory prostate cancer. The goal of hormone therapy is to reduce testosterone to what is called the castrate level, typically below 50 nanograms per deciliter. If your testosterone is not at this level, the cancer may not truly be hormone-refractory. Instead, it may simply mean that your hormone therapy is not working as intended, and a different approach might be needed.^[3]

Checking testosterone is often overlooked but is an essential part of the diagnostic process. It ensures that doctors are making decisions based on accurate information about how your body is responding to treatment.^[1]

Imaging Tests

Imaging tests help doctors see where the cancer is located and whether it has spread to other parts of the body. Several types of imaging are commonly used:

Bone scan: Prostate cancer often spreads to the bones, causing pain and other complications. A bone scan uses a small amount of radioactive material injected into a vein to highlight areas where cancer may be present in the skeleton. However, bone metastases from prostate cancer are typically osteoblastic, meaning they cause new bone growth rather than destroying bone. This makes them difficult to measure accurately on scans, especially when trying to determine if treatment is working.^[1]
CT scan (computed tomography): A CT scan creates detailed cross-sectional images of the body and can identify cancer in lymph nodes or soft tissues. It is often used to check whether cancer has spread beyond the prostate.^[4]
MRI scan (magnetic resonance imaging): MRI provides highly detailed images of soft tissues and can be particularly useful for examining the prostate and nearby structures.

Imaging tests may show that cancer is growing even when PSA levels are stable or falling, or they may reveal new areas of spread. Sometimes, no visible cancer is seen on scans even though PSA is rising. This situation is called non-metastatic castration-resistant prostate cancer, meaning the cancer is progressing but has not yet spread to detectable sites.^[4]

Physical Examination and Symptom Assessment

Your doctor will also perform a physical exam and ask about any new symptoms you may be experiencing. Symptoms such as bone pain, difficulty urinating, blood in the urine, extreme fatigue, unintended weight loss, or swelling in the legs can all suggest that cancer is progressing. A digital rectal exam, where the doctor feels the prostate through the rectal wall, may also be part of the evaluation.^[6]

These subjective measures are important because prostate cancer can affect quality of life in many ways. Understanding your symptoms helps doctors tailor treatment to your individual needs and provides a fuller picture of how the disease is impacting you.^[1]

Additional Blood Tests

In some cases, doctors may order additional blood tests to help monitor the cancer. For example, acid phosphatase is another protein that can be elevated in prostate cancer, especially in advanced cases. If PSA is no longer a reliable marker, acid phosphatase or other tests may provide useful information.^[8]

Blood tests can also check for anemia or other complications. Prostate cancer that spreads to the bone marrow can interfere with the production of red and white blood cells, leading to anemia, weakness, and increased risk of infection.^[8]

Diagnostics for Clinical Trial Qualification

If you are considering enrolling in a clinical trial, you will likely undergo additional diagnostic tests. Clinical trials are research studies that test new treatments, and they often have strict criteria about who can participate. These criteria help ensure that the trial results are accurate and that participants are likely to benefit from the experimental treatment.

To qualify for a clinical trial for hormone-refractory prostate cancer, you typically need to meet certain diagnostic benchmarks. These may include documentation that your PSA is rising despite hormone therapy and that your testosterone levels are at castrate levels. Many trials also require that you have at least two consecutive PSA increases, measured using a standardized method.^[1]

Imaging tests are often required to determine whether you have metastatic or non-metastatic disease. Some trials are designed specifically for patients whose cancer has spread to bones or other organs, while others focus on patients with rising PSA but no visible spread on scans. Knowing where your cancer is located helps researchers match you to the most appropriate trial.^[4]

Clinical trials may also require additional blood tests, biopsies, or other evaluations to confirm the characteristics of your cancer. For example, some newer treatments target specific genetic changes in cancer cells. If a trial is testing one of these targeted therapies, you may need a biopsy to analyze the genetic makeup of your cancer.^[12]

⚠️ Important

Clinical trials often require detailed and repeated testing to ensure accurate results. While this may seem burdensome, these tests help doctors learn whether new treatments are safe and effective. Participating in a trial can also give you access to cutting-edge therapies not yet widely available.

Standardized criteria have been developed to help define hormone-refractory prostate cancer for research purposes. One important recommendation comes from the PSA Working Group, which suggests a uniform way to report PSA responses in clinical trials. This helps researchers compare results across different studies and ensures that everyone is using the same definitions.^[1]

In addition to PSA and imaging, clinical trials may look at other endpoints such as pain relief, quality of life, and overall survival. These palliative endpoints are especially important in hormone-refractory prostate cancer, where the main goal of treatment is often to relieve symptoms and improve daily life rather than cure the disease. Measuring these outcomes requires questionnaires and regular follow-up to track how you are feeling over time.^[1]

Not all patients with hormone-refractory prostate cancer will qualify for every trial. Factors such as your age, other health conditions, prior treatments, how fast your PSA is rising, and whether you have symptoms can all influence eligibility. Your doctor can help you understand which trials might be right for you and what tests will be needed to enroll.^[3]

Prognosis and Survival Rate

Prognosis

The outlook for patients with hormone-refractory prostate cancer varies widely depending on several factors. One important factor is whether the cancer has spread to other parts of the body. Patients whose cancer has spread to the bones or other organs generally face a more serious prognosis than those with rising PSA levels but no visible spread on scans.^[12]

Another key factor is how quickly the PSA level is rising. A shorter PSA doubling time often indicates more aggressive disease and may be associated with a poorer prognosis. The presence of symptoms such as bone pain, difficulty urinating, or extreme fatigue can also signal more advanced disease.^[3]

Age and overall health also play a role. Younger patients with fewer other health problems may tolerate treatment better and have longer survival times. Additionally, how well the cancer responds to subsequent treatments, such as chemotherapy or newer hormone therapies, can significantly impact the disease course.^[12]

Survival Rate

Historically, patients with hormone-refractory prostate cancer were thought to have a median survival of 12 to 18 months after the cancer became resistant to hormone therapy. However, more recent studies suggest that survival times have improved, likely due to earlier detection with PSA testing and better treatment options.^[6]

In a more recent study, the median survival for patients with hormone-refractory prostate cancer who had bone metastases was about 40 months (just over three years). For those without bone metastases, median survival was even longer—about 68 months (nearly six years). These numbers represent the point at which half of patients are still alive, meaning that many patients live considerably longer.^[6]

Another study found that patients who had a 50% or greater decline in PSA after treatment had a median survival of 21 months, compared to only 8 months for those with less than a 50% decline. This highlights how response to treatment can strongly influence survival outcomes.^[1]

It is important to remember that these are statistical averages. Every person’s cancer is unique, and individual outcomes can vary greatly. Some patients live much longer than the median, especially with newer treatments that have become available in recent years.^[14]